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Introduction
This issue of Current Controlled Trials in Cardiovascular
Medicine contains two diametrically opposite views of
whether all patients with heart failure require an implanted
cardioverter-defibrillator (ICD) to prevent sudden death.
Hsia et al [1] propose targeting the general population
with mild to moderate heart failure with ‘empirical’ ICD
therapy. Goldstein [2] on the other hand argues that this
would represent a huge logistic and economic expense
and that it would therefore be necessary to firstly identify
the heart failure subpopulation that could benefit from this.
Before analysing the essence of this debate, let me first
point out areas of agreement. Both sets of authors agree
that angiotensin-converting-enzyme inhibitors (ACEIs)
have a major impact on the prognosis of heart failure. It is
the achievement of randomised clinical trials (RCTs) athat
there is agreement on this point. Until the results of the
CONSENSUS trial [3] were published, there was dis-
agreement on the role of ACEIs, particularly in severe
heart failure, because of their potential to reduce renal
function. In fact, the steering committee of CONSENSUS
was stunned when it was told by the data monitoring com-
mittee to stop the trial because of the large mortality
reduction conferred by enalapril. They thought that the trial
had to be stopped because of an excess mortality in the
enalapril group. Both sets of authors also agree on the
beneficial effect of beta-blockers. Again this is the
achievement of research. Until recently, prescribing a
beta-blocker for heart failure was considered malpractice
and a reason for firing the junior doctor who did so.
The essence of the debate
Let us now consider what I believe is the essence of the
debate between Goldstein [2] and Hsia et al [1]. The
crucial point seems to be that these authors disagree on
the amount of research that is required before one can
recommend targeting a large group of loosely defined
patients with a specific therapy, drug or otherwise. Implan-
tation of a defibrillator is a particular type of antiarrhythmic
therapy. As far as anti-arrhythmic therapy is concerned,
progress through research has been less straightforward
than for ACEIs and beta-blockers. Twenty years ago it
would be hard to come home from a major cardiology
meeting without having been exposed to the dogma about
sudden death prevention that prevailed at the time. This
dogma was based on two correct clinical observations:
first, ventricular arrhythmia is a risk factor for sudden death
in patients with heart disease; second, there are drugs
that suppress arrhythmias. From this, it was concluded
that patients with heart disease should be targeted with
procedures to detect arrhythmias, followed by drug treat-
ment if arrhythmias were observed. The proponents of the
dogma had little evidence from RCTs to prove their point,
and the evidence available at the time did not support it. In
fact, the whole thinking was based on a misconception
that has proved difficult to jettison throughout the history
of medicine, namely that removing the risk factor must log-
ically also remove the risk. Nonetheless, the industry
jumped on to this bandwagon by providing the ambulatory
ECG equipment and the drugs required, and by promoting
their widespread application. It took a rethinking of the
whole concept [4] and the CAST study [5,6] to prove thathttp://cvm.controlled-trials.com/content/1/2/092
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the practice of arrhythmia detection and suppression with
the drugs used at the time was in fact a pipe dream that
was killing rather than saving patients. ‘Practice’ was put
in italics to stress that the issue here is not just the effi-
cacy of a single drug, but of a particular type of clinical
practice as a whole. 
Admittedly, the practice of implanting an automatic defibril-
lator is different from the practice that was tested by CAST.
The ICD has undoubtedly a much sounder pathophysio-
logic basis than the administration of drugs such as
encainide and flecainide, among others. As pointed out by
both Goldstein [2] and Hsia  et al [1], ICD therapy is also
supported by evidence from RCTs. Nonetheless, the
lesson learnt from the history of antiarrhythmic treatment
must not be forgotten. Interestingly, the largest ICD trial
performed thus far did not show improved survival. This trial
compared the policies of ICD versus no ICD in patients
with left-ventricular dysfunction and ECG abnormalities
who were undergoing coronary artery bypass surgery [7].
Neither Goldstein nor Hsia et al mention this. The trials
quoted by Hsia et al to support their view [1] are relatively
small and used mostly amiodarone as control. This raises
the complex issue of how effective the latter is in improving
survival. Furthermore, cynics would argue that we would
probably not have heard that much about these trials had
the results been negative. ACEIs and beta-blockers are
probably the best-researched drugs used in clinical prac-
tice today. With these compounds, large RCTs have been
done in a broad spectrum of patients. In total, thousands of
patients have been studied. Other than the influence of the
economics of the industries involved, it is difficult to see
why the widespread use of ICDs should be recommended
on the basis of evidence that is much more limited than the
evidence that supports the use of ACEIs and beta-block-
ers. This is particularly so because the currently available
evidence supporting ICDs leaves a number of questions
unanswered. Some of these were are also raised by Gold-
stein [2] and by Hsia et al [1]. Do ICDs confer an additional
reduction of total mortality on low-risk heart failure patients
who are optimally treated medically? No treatment is risk-
free. While this applies also to drugs, the risks associated
with ICD implantation may not be worth taking in low-risk
patients. (Sheldon et al [8] provide evidence for this from
the Canadian Implantable Defibrillator Study [9].) Should
ICDs be limited to patients who do not tolerate a beta-
blocker, or do they also confer additional benefit to patients
who are already using a beta-blocker? In patients with very
sick hearts, does cardioversion for VF – or pacing for asys-
tole – restore autonomous pump function for any length of
time? Does the aetiology of heart failure have any bearing
on the usefulness of ICDs? Hsia et al [1] point to the pos-
sibility of combining an automatic defibrillator and biventric-
ular pacing functions in one device. But how effective is
biventricular pacing in heart failure in the first place? Finally,
there is the question of cost-effectiveness. Procedures
such as implantation of an automatic cardioverter-defibrilla-
tor are expensive. We forget too easily that the use of
brand-name drugs for years on end is expensive too. It
follows that the cost-effectiveness of ICDs must be care-
fully considered for specific subgroups of patients. Hsia et
al make no attempt to address the cost-effectiveness issue.
Conclusion
In conclusion, it seems too early to follow Hsia et al as far
as the widespread empirical application of ICDs in heart
failure is concerned. Goldstein does not stand alone in this
regard [10]. Larger trials than those carried out thus far are
needed before current recommendations for ICD use [11]
can be relaxed. As in trials of bypass surgery, two policies
should be compared: ‘ICD now’ versus the policy of using
ICD only after resuscitable cardiac arrest. The primary end
point should be total mortality and in the analysis ‘cross-
over’ should be ignored. All patients should receive optimal
drug therapy. Appropriate subgroup analyses and multiat-
tribute risk stratification such as those used by Sheldon et
al [8] should be prespecified in the protocol, and detailed
pharmaco-economic data should be collected. We shall
have to wait and see whether the trials underway quoted
by Goldstein [2] and by Hsia et al [1] have eventually fol-
lowed this pattern when the results are published.
Debates such as the one between Goldstein and Hsia et
al in this issue of Current Controlled Trials in Cardiovas-
cular Medicine serve the important purpose of defining
directions for research. In the mean time clinical practice
should follow established recommendations until these
have been adapted by evidence-based communis opinio.
Here the following applies: don’t vote for the opposition
before it has come to power…
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